Literature DB >> 17103458

A variable combination of features of Noonan syndrome and neurofibromatosis type I are caused by mutations in the NF1 gene.

Ulrike Hüffmeier1, Martin Zenker, Juliane Hoyer, Raimund Fahsold, Anita Rauch.   

Abstract

Signs of neurofibromatosis type 1 (NF1) and Noonan syndrome (NS), two distinct autosomal dominant disorders, occur together in patients reported as Watson syndrome (WS), neurofibromatosis-Noonan syndrome (NFNS), partial LEOPARD syndrome, NS with features of NF1, and NF1 with Noonan-like features. The molecular basis of these combined phenotypes was poorly understood and controversially discussed over several decades. Only recently, there is increasing evidence for WS and NFNS being allelic to NF1 in the majority of patients. In this study we describe seven novel patients from five unrelated families with variable phenotypes of the NF1-NS spectrum which were systematically analyzed for mutations in the disease-causing genes NF1 for NF1 and PTPN11 for NS. Heterozygous mutations or deletions of NF1 were identified in all patients, while no PTPN11 mutation was found. The NF1 mutation segregated with the phenotype in both familial cases. These results support the hypothesis that variable phenotypes of the NF1-NS spectrum represent variants of NF1 in the majority of cases. Constitutive deregulation of the Ras pathway either through activating mutations of PTPN11 or through haploinsufficiency of neurofibromin, which acts as a Ras-inactivating GTP-ase, is probably the common pathogenetic mechanism explaining the phenotypic overlap of NS and NF1. (c) 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17103458     DOI: 10.1002/ajmg.a.31547

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  14 in total

1.  Noonan syndrome: clinical aspects and molecular pathogenesis.

Authors:  M Tartaglia; G Zampino; B D Gelb
Journal:  Mol Syndromol       Date:  2010-01-15

2.  Neurofibromatosis Type 1 Presenting with Ophthalmic Features: A Case Series.

Authors:  Gunjan Jain; Vaibhav Kumar Jain; Indra Kumar Sharma; Reena Sharma; Neeraj Saraswat
Journal:  J Clin Diagn Res       Date:  2016-11-01

Review 3.  Disorders of dysregulated signal traffic through the RAS-MAPK pathway: phenotypic spectrum and molecular mechanisms.

Authors:  Marco Tartaglia; Bruce D Gelb
Journal:  Ann N Y Acad Sci       Date:  2010-10-19       Impact factor: 5.691

Review 4.  Noonan syndrome and clinically related disorders.

Authors:  Marco Tartaglia; Bruce D Gelb; Martin Zenker
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2011-02       Impact factor: 4.690

Review 5.  LZTR1 molecular genetic overlap with clinical implications for Noonan syndrome and schwannomatosis.

Authors:  Kirsten M Farncombe; Emily Thain; Carolina Barnett-Tapia; Hamid Sadeghian; Raymond H Kim
Journal:  BMC Med Genomics       Date:  2022-07-15       Impact factor: 3.622

6.  A new nonsense mutation in the NF1 gene with neurofibromatosis-Noonan syndrome phenotype.

Authors:  Sevgi Yimenicioğlu; Ayten Yakut; Kadri Karaer; Martin Zenker; Arzu Ekici; Kürşat Bora Carman
Journal:  Childs Nerv Syst       Date:  2012-09-11       Impact factor: 1.475

7.  Increased rate of missense/in-frame mutations in individuals with NF1-related pulmonary stenosis: a novel genotype-phenotype correlation.

Authors:  Shay Ben-Shachar; Shlomi Constantini; Hen Hallevi; Emma K Sach; Meena Upadhyaya; Gareth D Evans; Susan M Huson
Journal:  Eur J Hum Genet       Date:  2012-10-10       Impact factor: 4.246

Review 8.  The RASopathies.

Authors:  Katherine A Rauen
Journal:  Annu Rev Genomics Hum Genet       Date:  2013-07-15       Impact factor: 8.929

Review 9.  Rosette forming glioneuronal tumor in association with Noonan syndrome: pathobiological implications.

Authors:  M Karafin; G I Jallo; M Ayars; C G Eberhart; F J Rodriguez
Journal:  Clin Neuropathol       Date:  2011 Nov-Dec       Impact factor: 1.368

Review 10.  An unexpected new role of mutant Ras: perturbation of human embryonic development.

Authors:  Christian P Kratz; Charlotte M Niemeyer; Martin Zenker
Journal:  J Mol Med (Berl)       Date:  2007-01-09       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.